# 1. Financial Performance ## A. Key Figures * **Total Operating Income:** **₹128 Cr** Q1 FY2026 (+35%) · **₹95 Cr** Q1 FY2025 * EBITDA: ₹24 Cr (18.79% margin) · ₹21 Cr prior year * **Net Loss:** **₹101 Cr** (PAT margin: -79%) · **₹13 Cr** net loss (-38% margin) prior year ## B. Revenue Growth * **Resilient Top-Line:** Solid double-digit revenue growth achieved despite operational disruption in final days of Q1. * **Near-Term Revenue Impact:** Estimated **INR60 crores** revenue loss expected over next six months due to incident. ## C. Profit Margins * **Margin Pressure from Disruption:** EBITDA margins compressed by ~300 bps due to Hyderabad unit shutdown, though insurance expected to cover operational losses. * **Gross Margin Decline Explained:** YoY gross margin compression driven by **undispatched shipments in June**, triggering inventory write-downs under accounting rules. * **Bottom-Line Protection:** No material bottom-line impact anticipated due to **business interruption insurance** covering profit loss; EBITDA margin outlook remains stable at **18–20%**. ## D. Cash Flow Trends * **Working Capital Deterioration:** Working capital days elevated to **193**, reflecting post-incident operational lag. * **Improvement Plan in Motion:** Target to reduce working capital days to **below 90 by end-FY26**, signaling aggressive recovery roadmap. * **Low Fixed Costs During Downtime:** Non-operational overheads minimal during shutdown, limiting incremental cash outflow. --- # 2. Segment & Revenue Mix ## A. Key Figures * **API Revenue:** **₹9 Cr** (Q1) → projected **₹70 Cr** (FY26E) * **O&M Revenue:** **₹13 Cr** (Q1) * **Segment Revenue Mix:** **80%-85%** from MCC (current) → targeted **~75%** (forward) * **API EBITDA Margin:** **18%-20%** (annual projection) ## B. MCC Contribution * **Core Revenue Driver:** MCC remains the dominant segment, contributing the majority of sales, with strong export orientation accounting for **80% of its revenue**. * **Volume-Lead Divergence:** Despite representing nearly **30% of total production volume**, MCC contributed only **20% of total revenue**, signaling a lower realization intensity versus other segments. * **Strategic De-emphasis:** Company plans to reduce MCC’s revenue share to **~75%**, prioritizing diversification into higher-margin API and O&M streams. ## C. API Revenue Outlook * **High-Growth Trajectory:** API revenue on track for **strong multi-fold expansion** to ₹70 Cr by FY26, despite a seasonal decline in the current quarter. * **Domestic & ROW-Focused Growth:** Near-term revenue visibility anchored in **non-European markets**, with minimal contribution expected from EU exports. * **Margin Profile Clarity:** API segment targeted for **sustainable 18%-20% EBITDA margins**, indicating confidence in operational scalability and pricing power. ## D. O&M Services Growth * **Emerging Income Pillar:** O&M services now established as a **stable and scalable** revenue stream, with continued year-on-year growth momentum. * **Diversification Progress:** Combined non-MCC segments (O&M + API) generated **₹22 Cr** in Q1 revenue, reinforcing successful portfolio broadening. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Total Installed Capacity:** **~24,000 MT/year** (Hyderabad unit: **6,400 MT/year**, 29% of total) * **Production Impact:** **30% of volumes** expected to be affected over next six months * **CCS Expansion Timeline:** Target completion by **October '26** ## B. Plant Shutdown Impact * **Major Unit Offline:** The Hyderabad (Pashamylaram) facility remains under temporary shutdown for ~180 days, with no access yet granted to assess damage or equipment status. * **Restart Contingency:** Management is evaluating multiple restart plans (A–D), with decisions contingent on customer timelines and facility handover. * **Restart Outlook:** Operations expected to resume within **6 months** of facility handover, subject to access and recovery progress. ## C. Production Relocation * **Capacity Reallocated:** Production from Hyderabad has been shifted to Dahej and Jhagadia units, which are operating smoothly amid the disruption. * **Strategic Site Secured:** Company has finalized terms for a new bulk drug and specialty chemical unit in Orvakal, Andhra Pradesh, advancing vertical integration goals. ## D. CCS Expansion Progress * **Expansion On Track:** CCS capacity expansion at Dahej is progressing on schedule with full-speed construction, supporting long-term integration and growth. * **Commercialization Underway:** CCS facility at Dahej is moving steadily toward commercial operations. --- # 4. Product & Regulatory Progress ## A. Key Figures * **CEP Filings:** **4** filed (including metformin, approved) * **Specialty Mix:** **~20%** of total volumes ## B. CEP Filings & Approvals * **European Market Access:** Regulatory progress at Trimax Raichur unit enables entry into Europe, with metformin CEP approved and additional filings in pipeline. * **Strategic Innovation Push:** Partnership with Respilon Group via MOU to integrate **NUENEX nanofiber technology** for advanced drug delivery systems. ## C. R&D Center Launch * **Regulatory Capability Buildout:** Hyderabad R&D center launching 28th July to enhance API development and analytical capabilities, supporting regulated market expansion. ## D. Specialty Product Mix * **Margin-Enhancing Portfolio Shift:** Specialty and co-process grades represent a meaningful share of volumes, delivering significantly better margins than standard offerings. --- # 5. Customer & Supply Continuity ## A. Key Figures * **Lost Revenue:** **₹4 Cr** due to undispersed goods (to be recovered in current quarter) * **O&M Contribution:** **<10%** of revenue this quarter ## B. Client Support Level * **Strong Client Backing:** Sales team actively managing communication, with clients demonstrating loyalty through advance payments and written support. * **Retention Outlook:** Management views supply disruption as temporary and expects customer return post-recovery, despite limited formal assessment beyond **180-day timeline**. ## C. Volume Realizations * **Revenue Recovery Path:** Lost volume from undispersed stock to be shipped in current quarter, with minimal impact on overall revenue mix. * **Price Stability:** MCC prices for both inputs and finished goods remain stagnant, indicating no near-term margin pressure from cost fluctuations. --- # 6. Risks & Safety Factors ## A. Key Figures * **Total Incident Loss:** **₹121 Cr** (fixed assets: ₹51.48 Cr, stock: ₹7.66 Cr, compensation: ₹59.35 Cr, GST reversal: ₹2.52 Cr) * **Insurance Claim Filed:** **~₹90 Cr** (est. up to **₹100 Cr**) ## B. Incident Investigation * **Tragic Operational Event:** Fatal fire at Hyderabad unit caused by suspected dust explosion in spray drying machine, with full medical and financial support extended to affected families. * **Ongoing Root-Cause Assessment:** Government-appointed expert committee (IICT, fire specialists) conducting formal inquiry; findings expected by end-July, with internal and external reviews underway. * **Proactive Safety Response:** Re-safety audits completed at Dahej and Jhagadia plants; task force established for compliance and operational continuity. * **Management Stance on Allegations:** Denial of pre-incident safety warnings; media reports deemed inaccurate, with emphasis on existing ISO45001 certification and functional safety systems. ## C. Insurance Claim Status * **Conservative Accounting Treatment:** Full loss recognized in current quarter; insurance recoveries, including for business interruption and asset replacement, to be recorded as future income. * **High Confidence in Recovery:** Claim covers rebuilding value of fixed assets and lost profits, with no current indication of rejection—even under worst-case liability scenarios. ## D. Regulatory Compliance * **NOC Clarification:** Fire NOC not legally required for Hyderabad plant due to structural specifications; absence would have triggered shutdown if mandatory. --- # 7. Guidance & Outlook ## A. Key Figures * **API Revenue:** **₹70 Cr** expected this year, projected to grow **2–3x** in coming years * **Revenue Impact:** **₹60 Cr** negative impact over next 6 months · Revised revenue guidance: **₹550–575 Cr** * **Lost Revenue:** **₹60 Cr** from Hyderabad unit over 180 days · Net loss estimated at **₹40 Cr** * **Capex Recovery:** **~₹20 Cr** of lost revenue recoverable via Dahej/Jhagadia capacity utilization ## B. Revenue Projections * **Growth Trajectory:** API business poised for strong multi-year expansion on new molecules and higher-value product mix, despite near-term headwinds. * **Near-Term Disruption:** Hyderabad unit outage removes **₹60 Cr** of expected revenue, creating a temporary dip with recovery anticipated post-restoration. * **Revised Outlook:** Full-year revenue guidance adjusted to **₹550–575 Cr** range due to plant shutdown; prior target was at least **25% YoY growth**. ## C. Capex & Insurance Use * **Full Capex Coverage:** Restoration capex expected to be fully funded by insurance proceeds, with no incremental debt or equity anticipated. * **Uncertain Capex Timing:** Exact capex requirement remains undetermined due to restricted site access and ongoing damage assessment. ## D. Operational Recovery Timeline * **Recovery Path Dependent:** Full restoration timeline hinges on return of facility control; detailed plan await access and assessment. * **CCS Launch Unaffected:** Management sees no delays in government approvals and remains confident in **October 2026 launch** for CCS facility. * **Insurance Timing Critical:** Claim disbursement schedule will materially influence **bottom line growth** trajectory; timely receipt supports recovery outlook.